Clinical Trial Update: Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects [Phase 2]

View source ↗

Summary

Phase 2 trial updates the safety and efficacy of the LDV/SOF fixed-dose combination with or without ribavirin in chronic hepatitis C genotype 1 patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• LDV/SOF fixed-dose combination (ledipasvir/sofosbuvir)
• Ribavirin (ribavirin)

Snippet

Sponsor: Gilead Sciences | Conditions: Chronic Hepatitis C Virus | Phase 2 | Status: COMPLETED | Results posted: 2014-11-17